
Prothena Corporation plc PRTA
$ 8.39
1.7%
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
53.8 M |
Market Cap[1] |
$ 452 M |
EBITDA (LTM) |
$ -214 M |
P/E (LTM) |
-2.16777 |
P/S (LTM) |
54.584963 |
EPS (LTM) |
-4.53 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Armata Pharmaceuticals
ARMP
|
$ 3.16 | 2.27 % | $ 115 M | NYSE American | ||
|
Axon Enterprise
AXON
|
$ 424.49 | 1.9 % | $ 33.1 B | Nasdaq Global Select Market,SPB | ||
|
Axsome Therapeutics
AXSM
|
$ 136.95 | -1.91 % | $ 6.81 B | Nasdaq Global Market,SPB | ||
|
Biogen
BIIB
|
$ 254.56 | 2.26 % | $ 37.3 B | Nasdaq Global Select Market,SPB | ||
|
BioLineRx Ltd.
BLRX
|
$ 1.87 | -2.09 % | $ 4.61 B | Nasdaq Capital Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 1.67 | 3.73 % | $ 2.75 M | NYSE American | ||
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | Nasdaq Capital Market | ||
|
Celldex Therapeutics
CLDX
|
$ 29.92 | 0.71 % | $ 1.99 B | Nasdaq Global Select Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
AIM ImmunoTech
AIM
|
$ 0.16 | 1.12 % | $ 259 K | NYSE American | ||
|
Ascendis Pharma A/S
ASND
|
$ 257.48 | 2.92 % | $ 15.6 B | Nasdaq Global Select Market | ||
|
ANI Pharmaceuticals
ANIP
|
$ 71.6 | -0.94 % | $ 1.44 B | Nasdaq Global Market,SPB | ||
|
Actinium Pharmaceuticals
ATNM
|
$ 1.42 | 1.43 % | $ 44.3 M | NYSE American | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.37 | -3.53 % | $ 365 M | Nasdaq Global Select Market | ||
|
BridgeBio Pharma
BBIO
|
$ 77.85 | 5.16 % | $ 14.9 B | Nasdaq Global Select Market,SPB | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 8.26 | -3.68 % | $ 1.73 B | Nasdaq Global Select Market | ||
|
Bicycle Therapeutics plc
BCYC
|
$ 3.72 | 1.36 % | $ 258 M | Nasdaq Global Select Market | ||
|
Coherus BioSciences
CHRS
|
$ 0.85 | 5.95 % | $ 99.6 M | Nasdaq Global Market | ||
|
Arcutis Biotherapeutics
ARQT
|
$ 34.23 | 6.95 % | $ 4.36 B | Nasdaq Global Select Market,SPB | ||
|
Cellectis S.A.
CLLS
|
$ 1.14 | 4.59 % | $ 114 M | Nasdaq Global Market | ||
|
BeyondSpring
BYSI
|
$ 0.68 | 9.47 % | $ 28 M | Nasdaq Capital Market | ||
|
Alkermes plc
ALKS
|
$ 45.87 | 0.38 % | $ 7.55 B | Nasdaq Global Select Market | ||
|
Altimmune
ALT
|
$ 2.1 | 2.94 % | $ 185 M | Nasdaq Global Market | ||
|
Arcturus Therapeutics Holdings
ARCT
|
$ 10.84 | 13.63 % | $ 297 M | Nasdaq Global Market,SPB | ||
|
Arrowhead Pharmaceuticals
ARWR
|
$ 61.68 | 3.61 % | $ 8.25 B | Nasdaq Global Select Market,SPB | ||
|
Atara Biotherapeutics
ATRA
|
$ 8.4 | 2.44 % | $ 105 M | Nasdaq Global Select Market,SPB | ||
|
Aurinia Pharmaceuticals
AUPH
|
$ 17.11 | 3.35 % | $ 2.3 B | Nasdaq Global Market | ||
|
Cullinan Management
CGEM
|
$ 12.53 | -20.44 % | $ 755 M | Nasdaq Global Select Market | ||
|
BioNTech SE
BNTX
|
$ 90.3 | 3.89 % | $ 21.8 B | Nasdaq Global Select Market | ||
|
Collegium Pharmaceutical
COLL
|
$ 23.66 | -0.32 % | $ 749 M | Nasdaq Global Select Market | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 3.59 | -7.24 % | $ 47.8 M | Nasdaq Global Market | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.4 | -4.11 % | $ 64 M | Nasdaq Capital Market | ||
|
AnaptysBio
ANAB
|
$ 47.52 | -0.44 % | $ 1.38 B | Nasdaq Global Select Market,SPB | ||
|
Assembly Biosciences
ASMB
|
$ 19.81 | -0.55 % | $ 222 M | Nasdaq Global Select Market,SPB | ||
|
Adagene
ADAG
|
$ 2.43 | 3.4 % | $ 143 M | Nasdaq Global Market | ||
|
Benitec Biopharma
BNTC
|
$ 9.07 | 7.98 % | $ 422 M | Nasdaq Capital Market | ||
|
Denali Therapeutics
DNLI
|
$ 20.93 | 7.61 % | $ 3.61 B | Nasdaq Global Select Market,SPB | ||
|
Amarin Corporation plc
AMRN
|
$ 12.29 | 1.99 % | $ 5.1 B | Nasdaq Global Market | ||
|
Editas Medicine
EDIT
|
$ 2.72 | 4.62 % | $ 241 M | Nasdaq Global Select Market,SPB | ||
|
Agios Pharmaceuticals
AGIO
|
$ 31.42 | 0.71 % | $ 1.82 B | Nasdaq Global Select Market,SPB | ||
|
Cue Biopharma
CUE
|
$ 19.81 | -5.03 % | $ 1.88 B | Nasdaq Capital Market,SPB | ||
|
Equillium
EQ
|
$ 1.39 | -1.42 % | $ 79.7 M | Nasdaq Global Market | ||
|
Black Diamond Therapeutics
BDTX
|
$ 1.9 | 4.97 % | $ 108 M | Nasdaq Global Select Market,SPB | ||
|
Abeona Therapeutics
ABEO
|
$ 4.22 | -0.82 % | $ 223 M | Nasdaq Capital Market | ||
|
ACADIA Pharmaceuticals
ACAD
|
$ 21.49 | 4.47 % | $ 3.62 B | Nasdaq Global Select Market,SPB | ||
|
Atossa Therapeutics
ATOS
|
$ 2.12 | -9.01 % | $ 18.3 M | Nasdaq Capital Market | ||
|
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | Nasdaq Capital Market | ||
|
AC Immune SA
ACIU
|
$ 2.25 | 7.66 % | $ 227 M | Nasdaq Global Market | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | Nasdaq Global Select Market | ||
|
ADC Therapeutics SA
ADCT
|
$ 1.72 | 10.65 % | $ 219 M | NYSE |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.